Comparison Overview

Lincoln Pharmaceuticals Ltd

VS

Dr. Reddy's Laboratories

Lincoln Pharmaceuticals Ltd

Science City Road, Ahmedabad, Gujarat, 380060, IN
Last Update: 2025-05-06 (UTC)
View Profile
Between 750 and 799
https://www.lincolnpharma.com

Lincoln is proud of its manufacturing capabilities. We are really distinct and powerful when it comes to the production capacity. Set up in the year 1979, the manufacturing facility of Lincoln is based at Khatraj, Gujarat sharing the same dais as with the international standards. Another manufacturing setup at Mehsana, Gujarat and Head Office in Ahemedabad city of Gujarat. There are global standards and norms which a manufacturing lab should scan through and we ensure that our processes are in compliance with WHO-cGMP norms. Our lab has been given ISO 9001:2015 certifications; thoroughly highlighting Lincoln’s dedication in direction of high quality and safety. These certifications and achievement has added new feather to out hat. With these achievements, we also furthermore plan to expand the capabilities in the US and UK markets making the presence global and more rewarding.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 807
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, None, Hyderabad, TS, IN, 500034
Last Update: 2025-07-29 (UTC)
Between 750 and 799
http://www.drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com.  Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages.  Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 30,286
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/lincoln-pharmaceuticals-ltd.jpeg
Lincoln Pharmaceuticals Ltd
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/dr--reddys-laboratories.jpeg
Dr. Reddy's Laboratories
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Lincoln Pharmaceuticals Ltd
100%
Compliance Rate
0/4 Standards Verified
Dr. Reddy's Laboratories
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Lincoln Pharmaceuticals Ltd in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Dr. Reddy's Laboratories in 2025.

Incident History — Lincoln Pharmaceuticals Ltd (X = Date, Y = Severity)

Lincoln Pharmaceuticals Ltd cyber incidents detection timeline including parent company and subsidiaries

Incident History — Dr. Reddy's Laboratories (X = Date, Y = Severity)

Dr. Reddy's Laboratories cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/lincoln-pharmaceuticals-ltd.jpeg
Lincoln Pharmaceuticals Ltd
Incidents

No Incident

https://images.rankiteo.com/companyimages/dr--reddys-laboratories.jpeg
Dr. Reddy's Laboratories
Incidents

No Incident

FAQ

Dr. Reddy's Laboratories company demonstrates a stronger AI Cybersecurity Score compared to Lincoln Pharmaceuticals Ltd company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Dr. Reddy's Laboratories company has disclosed a higher number of cyber incidents compared to Lincoln Pharmaceuticals Ltd company.

In the current year, Dr. Reddy's Laboratories company and Lincoln Pharmaceuticals Ltd company have not reported any cyber incidents.

Neither Dr. Reddy's Laboratories company nor Lincoln Pharmaceuticals Ltd company has reported experiencing a ransomware attack publicly.

Neither Dr. Reddy's Laboratories company nor Lincoln Pharmaceuticals Ltd company has reported experiencing a data breach publicly.

Neither Dr. Reddy's Laboratories company nor Lincoln Pharmaceuticals Ltd company has reported experiencing targeted cyberattacks publicly.

Neither Lincoln Pharmaceuticals Ltd company nor Dr. Reddy's Laboratories company has reported experiencing or disclosing vulnerabilities publicly.

Neither Lincoln Pharmaceuticals Ltd nor Dr. Reddy's Laboratories holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Lincoln Pharmaceuticals Ltd company nor Dr. Reddy's Laboratories company has publicly disclosed detailed information about the number of their subsidiaries.

Dr. Reddy's Laboratories company employs more people globally than Lincoln Pharmaceuticals Ltd company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Lincoln Pharmaceuticals Ltd nor Dr. Reddy's Laboratories holds SOC 2 Type 1 certification.

Neither Lincoln Pharmaceuticals Ltd nor Dr. Reddy's Laboratories holds SOC 2 Type 2 certification.

Neither Lincoln Pharmaceuticals Ltd nor Dr. Reddy's Laboratories holds ISO 27001 certification.

Neither Lincoln Pharmaceuticals Ltd nor Dr. Reddy's Laboratories holds PCI DSS certification.

Neither Lincoln Pharmaceuticals Ltd nor Dr. Reddy's Laboratories holds HIPAA certification.

Neither Lincoln Pharmaceuticals Ltd nor Dr. Reddy's Laboratories holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References